A combinatorial therapeutic regimen of cotreatment with AQB and inhibitor of lysine-specific demethylase 1 or LSD1, GSK-LSD1 has also been propounded as an efficient therapeutic strategy against gliomas (Zhao et al. 2021). Here, KDM1A is linked to glioma.